Ul­tragenyx opens new gene ther­a­py man­u­fac­tur­ing site in Mass­a­chu­setts

The rare dis­ease play­er Ul­tragenyx will pro­duce its gene ther­a­pies in-house as it opens the doors to a new man­u­fac­tur­ing fa­cil­i­ty, which will lessen its re­liance on ex­ter­nal con­tract man­u­fac­tur­ers.

Ul­tragenyx an­nounced Wednes­day that it of­fi­cial­ly opened its 110,000-square-foot man­u­fac­tur­ing fa­cil­i­ty on a 10.7-acre site in the Boston sub­urb of Bed­ford, MA. The site en­ables Ul­tragenyx to pro­duce gene ther­a­pies in 2,000-liter batch­es ver­sus the in­dus­try stan­dard of 50 liters per batch. Con­struc­tion on the site be­gan in 2020. The cost of the fa­cil­i­ty was not dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER